News | November 30, 2022
Gland Pharma to buy French pharma company Cenexi
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The product is expected to be launched by Q4 FY23.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
The Group will continue to make proactive investments of its management resources in the life science business
Subscribe To Our Newsletter & Stay Updated
